JP2022512911A5 - - Google Patents

Info

Publication number
JP2022512911A5
JP2022512911A5 JP2021524019A JP2021524019A JP2022512911A5 JP 2022512911 A5 JP2022512911 A5 JP 2022512911A5 JP 2021524019 A JP2021524019 A JP 2021524019A JP 2021524019 A JP2021524019 A JP 2021524019A JP 2022512911 A5 JP2022512911 A5 JP 2022512911A5
Authority
JP
Japan
Prior art keywords
inventions
patient
compound
administration
death
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021524019A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022512911A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/059632 external-priority patent/WO2020095274A1/en
Publication of JP2022512911A publication Critical patent/JP2022512911A/ja
Publication of JP2022512911A5 publication Critical patent/JP2022512911A5/ja
Priority to JP2024031803A priority Critical patent/JP2024081645A/ja
Priority to JP2025169038A priority patent/JP2026021335A/ja
Pending legal-status Critical Current

Links

JP2021524019A 2018-11-09 2019-11-08 ａｐｏ（ａ）を標的化するコンジュゲートアンチセンス化合物を用いて心血管事象のリスクを低減する方法 Pending JP2022512911A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024031803A JP2024081645A (ja) 2018-11-09 2024-03-04 ａｐｏ（ａ）を標的化するコンジュゲートアンチセンス化合物を用いて心血管事象のリスクを低減する方法
JP2025169038A JP2026021335A (ja) 2018-11-09 2025-10-07 ａｐｏ（ａ）を標的化するコンジュゲートアンチセンス化合物を用いて心血管事象のリスクを低減する方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862758323P 2018-11-09 2018-11-09
US62/758,323 2018-11-09
US201962874459P 2019-07-15 2019-07-15
US62/874,459 2019-07-15
PCT/IB2019/059632 WO2020095274A1 (en) 2018-11-09 2019-11-08 Method for reducing the risk of a cardiovascular event with conjugated antisense compounds targeting apo(a)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024031803A Division JP2024081645A (ja) 2018-11-09 2024-03-04 ａｐｏ（ａ）を標的化するコンジュゲートアンチセンス化合物を用いて心血管事象のリスクを低減する方法

Publications (2)

Publication Number Publication Date
JP2022512911A JP2022512911A (ja) 2022-02-07
JP2022512911A5 true JP2022512911A5 (https=) 2022-11-11

Family

ID=68582078

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021524019A Pending JP2022512911A (ja) 2018-11-09 2019-11-08 ａｐｏ（ａ）を標的化するコンジュゲートアンチセンス化合物を用いて心血管事象のリスクを低減する方法
JP2024031803A Pending JP2024081645A (ja) 2018-11-09 2024-03-04 ａｐｏ（ａ）を標的化するコンジュゲートアンチセンス化合物を用いて心血管事象のリスクを低減する方法
JP2025169038A Pending JP2026021335A (ja) 2018-11-09 2025-10-07 ａｐｏ（ａ）を標的化するコンジュゲートアンチセンス化合物を用いて心血管事象のリスクを低減する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024031803A Pending JP2024081645A (ja) 2018-11-09 2024-03-04 ａｐｏ（ａ）を標的化するコンジュゲートアンチセンス化合物を用いて心血管事象のリスクを低減する方法
JP2025169038A Pending JP2026021335A (ja) 2018-11-09 2025-10-07 ａｐｏ（ａ）を標的化するコンジュゲートアンチセンス化合物を用いて心血管事象のリスクを低減する方法

Country Status (9)

Country Link
US (2) US20210395737A1 (https=)
EP (1) EP3877523A1 (https=)
JP (3) JP2022512911A (https=)
KR (2) KR20260037169A (https=)
CN (1) CN113286885A (https=)
AU (3) AU2019377275A1 (https=)
CA (1) CA3111382A1 (https=)
IL (1) IL281147A (https=)
WO (1) WO2020095274A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021013807A2 (pt) 2019-01-18 2021-11-30 Astrazeneca Ab Inibidores de pcsk9 e seus métodos de uso
MX2021008661A (es) 2019-01-18 2021-08-19 Astrazeneca Ab Inhibidores de la pcsk9 y metodos de uso de los mismos.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5599706A (en) 1994-09-23 1997-02-04 Stinchcomb; Dan T. Ribozymes targeted to apo(a) mRNA
US7227014B2 (en) 2001-08-07 2007-06-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein (a) expression
US7259150B2 (en) 2001-08-07 2007-08-21 Isis Pharmaceuticals, Inc. Modulation of apolipoprotein (a) expression
WO2003014397A1 (en) 2001-08-09 2003-02-20 Biomedlab Corporation Probe for detection of enteric virus detection kit and method for enteric virus with the same
EP3822352A3 (en) 2012-05-24 2021-11-03 Ionis Pharmaceuticals, Inc. Methods and compositions for modulating apolipoprotein(a) expression
DK2992098T3 (da) 2013-05-01 2019-06-17 Ionis Pharmaceuticals Inc Sammensætninger og fremgangsmåder til modulering af hbv- og ttr-ekspression
US9382540B2 (en) * 2014-05-01 2016-07-05 Isis Pharmaceuticals, Inc Compositions and methods for modulating angiopoietin-like 3 expression
KR20250078597A (ko) 2015-11-06 2025-06-02 아이오니스 파마수티컬즈, 인코포레이티드 아포리포프로테인 (a) 발현 조정
PL4119569T3 (pl) * 2015-11-06 2024-11-18 Ionis Pharmaceuticals, Inc. Sprzężone związki antysensowne do zastosowania w terapii

Similar Documents

Publication Publication Date Title
JP2022062151A5 (https=)
Prys-Roberts et al. Efficacy and safety of doxazosin for perioperative management of patients with pheochromocytoma
ES2241305T3 (es) Combinaciones contra la diabetes que contienen gliburide, troglitazona (y una biguanida).
JP2023549115A5 (https=)
Bosch Medical treatment of portal hypertension
KR20110026422A (ko) 영구적 심방 세동의 예방을 위한 드로네다론
JP2022512911A5 (https=)
CA2979448A1 (en) Treat of type 2 diabetes mellitus patients
US20130123298A1 (en) Pharmaceutical composition for the prevention of perioperative arterial hypotension in humans
KR20120138229A (ko) 정맥내 투여용 이부프로펜을 이용한 중증 환자의 치료
KR20120089623A (ko) 정맥내 투여용 이부프로펜을 이용한 환자의 치료
ES2250749T3 (es) Uso de una composicion combinada que comprende propionil l-carnitina y otros farmacos para el tratamiento de la disfuncion erectil.
KR20140032380A (ko) 확장성 울혈성 심부전 치료제
Krott et al. Adjunctive hyperbaric oxygenation in macular edema of vascular origin
CN102149376B (zh) 症状性心力衰竭的长期治疗
Kambam et al. Histamine2 receptor blocker in the treatment of protamine related anaphylactoid reactions: two case reports
RU2022129009A (ru) Способ снижения риска развития сердечно-сосудистого события с помощью конъюгированных антисмысловых соединений, нацеливающихся на apo(a)
CA2889584C (en) Methods for controlling blood pressure and reducing dyspnea in heart failure
RU2021116145A (ru) Способ снижения риска развития сердечно-сосудистого события с помощью конъюгированных антисмысловых соединений, нацеливающихся на apo(a)
Iida et al. Treatment of dialysis-induced hypotension with L-threo-3, 4-dihydroxyphenylserine
Hamid et al. Hypotension following valve replacement surgery in carcinoid heart disease
AU2002220960A1 (en) Regeneration of blood vessels
EP1372629A2 (en) Therapeutic treatment
Horita et al. A case of the toxicity of pilsicainide hydrochloride with comparison of the serial serum pilsicainide levels and electrocardiographic findings
Prakash Nesiritide tops nitroglycerin in acute decompensated CHF